
Sign up to save your podcasts
Or
Host: Darryl S. Chutka, M.D. [@chutkaMD]
Guest: R. Jeffrey Karnes, M.D.
Prostate cancer is the most common solid organ malignancy in males, and it’s estimated that 1 in 8 men will develop prostate cancer during their lifetime. When diagnosed early, it has an excellent survival rate with a variety of very effective treatment options. What are the advantages and disadvantages of each? Why would one option be chosen over another and how do the adverse effects of the various treatments differ? In this podcast, I’ll be discussing these questions with our guest, R. Jeffrey Karnes, M.D., a urologist at the Mayo Clinic.
This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
4.4
259259 ratings
Host: Darryl S. Chutka, M.D. [@chutkaMD]
Guest: R. Jeffrey Karnes, M.D.
Prostate cancer is the most common solid organ malignancy in males, and it’s estimated that 1 in 8 men will develop prostate cancer during their lifetime. When diagnosed early, it has an excellent survival rate with a variety of very effective treatment options. What are the advantages and disadvantages of each? Why would one option be chosen over another and how do the adverse effects of the various treatments differ? In this podcast, I’ll be discussing these questions with our guest, R. Jeffrey Karnes, M.D., a urologist at the Mayo Clinic.
This episode is brought to you by: Astellas Oncology | https://astellasoncology.com/
Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
139 Listeners
322 Listeners
507 Listeners
695 Listeners
255 Listeners
3,338 Listeners
87 Listeners
23 Listeners
1,121 Listeners
197 Listeners
516 Listeners
362 Listeners
12 Listeners
18 Listeners
254 Listeners
15 Listeners
9 Listeners
423 Listeners
367 Listeners
46 Listeners
15 Listeners